Raleigh Capital Management Inc. Increases Holdings in AbbVie Inc. $ABBV

Raleigh Capital Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 17.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,091 shares of the company’s stock after purchasing an additional 2,730 shares during the period. AbbVie accounts for about 1.5% of Raleigh Capital Management Inc.’s holdings, making the stock its 12th largest holding. Raleigh Capital Management Inc.’s holdings in AbbVie were worth $4,552,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Landaas & Co. WI ADV grew its position in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 5,954 shares of the company’s stock worth $1,498,000 after buying an additional 66 shares during the last quarter. River Street Advisors LLC increased its stake in shares of AbbVie by 1.5% during the second quarter. River Street Advisors LLC now owns 13,777 shares of the company’s stock valued at $3,467,000 after buying an additional 205 shares during the period. Laurel Oak Wealth Management LLC raised its holdings in shares of AbbVie by 6.1% during the second quarter. Laurel Oak Wealth Management LLC now owns 3,889 shares of the company’s stock valued at $979,000 after acquiring an additional 224 shares in the last quarter. Evolution Wealth Management Inc. raised its holdings in shares of AbbVie by 11.2% during the second quarter. Evolution Wealth Management Inc. now owns 735 shares of the company’s stock valued at $185,000 after acquiring an additional 74 shares in the last quarter. Finally, Greenleaf Trust lifted its stake in AbbVie by 1.6% in the second quarter. Greenleaf Trust now owns 60,700 shares of the company’s stock worth $15,275,000 after acquiring an additional 962 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

Analyst Ratings Changes

A number of research analysts have issued reports on ABBV shares. Barclays boosted their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Evercore set a $235.00 price target on shares of AbbVie in a research report on Friday, May 15th. Finally, Cantor Fitzgerald increased their price target on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.50.

AbbVie Stock Performance

ABBV stock opened at $249.20 on Friday. The firm has a 50 day moving average price of $244.94 and a 200-day moving average price of $226.12. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm has a market capitalization of $440.29 billion, a price-to-earnings ratio of 70.40, a PEG ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.